Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3003 Phase I/II Study in Relapsed or Refractory Multiple Myeloma
CTR20243384Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Oct 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3003 in multiple myeloma (MM), sponsored by InnoCare Pharma. Started Oct 2024; status: active.
02
Drugs
IBI3003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20243384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243384.